Detection of prostate cancer and predicting progression: Current and future diagnostic markers

Clinical Cancer Research

Volumn 10, Issue 12 I, 2004, Pages 3943-3953

  Tricoli, James V ^a   Schoenfeldt, Mason ^b   Conley, Barbara A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b EMMES CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOGRANIN A; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE PI 1; MOLECULAR MARKER; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROSTATE STEM CELL ANTIGEN; TELOMERASE REVERSE TRANSCRIPTASE; TUMOR PROTEIN; UNCLASSIFIED DRUG;

BLOOD ANALYSIS; CANCER DIAGNOSIS; CANCER GENETICS; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; DIAGNOSTIC VALUE; EVALUATION; HISTOPATHOLOGY; HUMAN; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SEMEN ANALYSIS; SERUM; URINALYSIS; VALIDATION PROCESS;

ANTIGENS, SURFACE; CHROMOGRANIN A; CHROMOGRANINS; DISEASE PROGRESSION; DNA-BINDING PROTEINS; GLUTAMATE CARBOXYPEPTIDASE II; GLUTATHIONE TRANSFERASE; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; NEOPLASM PROTEINS; PROSTATIC NEOPLASMS; TELOMERASE; TUMOR MARKERS, BIOLOGICAL;

EID: 3042663483     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0200     Document Type: Review

References (135)

1. Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA-Cancer J Clin 2003;53:5-26.
2. Stamey TA, Donaldson AN, Yemoto CE, et al. Histological and clinical findings in 896 consecutive prostates treated only with radical retropubic prostatectomy: epidemiologic significance of annual changes. J Urol 1998;160:2412-7.
3. Stamey TA, Johnstone IM, Mcneal JE, Lu AY, Yemoto CM. Pre-operative serum prostate specific antigen levels between 2 and 22 ng/ml correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng/ml. J Urol 2002;167:103-11.
4. Brothman A. Cytogenetics and molecular genetics of cancer of the prostate. Am J Med Genet 2002;115:150-6.
5. Langstaff RH, Polskey HJ. Prostatic malignancy. In: Ballenger EG, Fontz WA, Hamer HG, Lewis B, editors. History of urology, vol. 2. Baltimore, MD: Wilkins & Wilkins Co., 1933; p. 187.
6. Kutscher W, Wolbergs H. Prostata phosphatase. Hoppe-Seyler's Z Physiol Chem 1935;236:237.
7. Gutman EB, Sproul EE, Gutman AB. Significance of increased phosphatase activity of bone at the site of osteoplastic metastases secondary to carcinoma of the prostate gland. Am J Cancer 1936;28: 485-95.
8. Gutman AB, Gutman EB. An acid phosphatase occurring in the serum of patients with metastasizing carcinoma of the prostate gland. J Clin Investig 1938;17:473-8.
9. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1:293-7.
10. Schacht MJ, Garnett JE, Grayhack JT. Biochemical markers in prostatic cancer. Urol Clin North Am 1984;11:253-67.
11. Sullivan TJ, Gutman EB, Gutman AB. Theory and application of the serum "acid" phosphatase determination in metastasizing prostatic carcinoma: early effects of castration. J Urol 1942;48:426-58.
12. Nesbit RM, Baum WB. Serum phosphatase determination in diagnosis of prostatic cancer. A review of 1,150 cases. JAMA 1951; 145:1321-4.
13. King EJ, Jegatheesan KA. A method of the determination of tartrate-labile prostatic acid phosphatase in serum. J Clin Pathol 1959; 12:85-9.
14. Ladenson JH. Nonanalytical sources of variation in clinical chemistry results. In: Sonnenwirth AC, Jarett L, editors. Gradwohl's Clinical Laboratory Methods and Diagnosis, 8th ed. St. Louis, MO: CV Mosby, 1980; p. 149-92.
15. Foti AG, Cooper JF, Herschman H, Malvaez RR. Detection of prostatic cancer by solid-phase radioimmunoassay of serum prostatic acid phosphatase. N Engl J Med 1977;297:1357-61.
16. Hara M, Koyanagi Y, Inoue T, Fukuyama T. Physico-chemical characteristics of "y-seminoprotein," an antigenic component specific for human seminal plasma. Jpn J Legal Med 1971;25:322-4.
17. Riegman PH, Vlietstra RJ, Klaassen P, et al. The prostate-specific antigen gene and the human glandular kallikrein-1 gene are tandemly located on chromosome 19. FEBS Lett 1989;247:123-6.
18. Dawson NA, Vogelzang NJ, editors. Prostate cancer. New York: Wiley-Liss, Inc.; 1994.
19. Papsidero LD, Wang MC, Valenzuela LA, Murphy GP, Chu TM. A prostate antigen in sera of prostatic cancer patients. Cancer Res 1980; 40:2428-32.
20. Myrtle JF, Klimley PG, Ivor LP, Bruni JF. Clinical utility of prostate specific antigen (PSA) in the management of prostate cancer. In: Advances in cancer diagnostics. San Diego, CA: Hybritech Inc., 1986; p. 1-4.
21. Brawer MK, Chetner MP, Beatie J, et al. Screening for prostatic carcinoma with prostate specific antigen. J Urol 1992;147:841-5.
22. Labrie F, Dupont A, Suburu R, et al. Serum prostate specific antigen as pre-screening test for prostate cancer. J Urol 1992;147:846-51; discussion, 851-2.
23. Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324:1156-61. Erratum in: N Engl J Med 1991;325:1324.
24. Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324:1156-61. Erratum in: N Engl J Med 1991;325:1324.
25. Cooner WH, Mosley BR, Rutherford CL Jr, et al. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol 1990;143:1146-52; discussion, 1152-4.
26. Wang TY, Kawaguchi TP. Preliminary evaluation of measurement of serum prostate-specific antigen level in detection of prostate cancer. Ann Clin Lab Sci 1986;16:461-6.
27. Guinan P, Bhatti R, Ray P. An evaluation of prostate specific antigen in prostatic cancer. J Urol 1987;137:686-9.
28. Stamey TA, Yang N, Hay AR, et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317:909-16.
29. Stamey TA. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. Monogr Urol 1989;10:49-56.
30. United States Food and Drug Administration Approval Document P850048. Use of PSA for disease monitoring, 1986.
31. United States Food and Drug Administration Approval Document P94-16. Use of PSA for prostate cancer screening, 1994.
32. Rebhan M, Chalifa-Caspi V, Prilusky J, Lancet D. GeneCards: encyclopedia for genes, proteins and diseases. Rehovot, Israel: Weizmann Institute of Science, Bioinformatics and Genome Center, 1997.
33. Simon JP, Aunis D. Biochemistry of the chromogranin A protein family. Biochem J 1989;262:1-13.
34. Blaschko H, Comline RS, Schneider FH, Silver M, Smith AD. Secretion of a chromaffin granule protein, chromogranin, from the adrenal gland after splanchnic stimulation. Nature (Lond) 1967;215: 58-9.
35. Berruti A, Dogliotti L, Mosca A, et al. Potential clinical value of circulating chromogranin A in patients with prostate carcinoma. Ann Oncol 2001;12:S153-7.
36. Wu JT, Astill ME, Liu GH, Stephenson RA. Serum chromogranin A: early detection of hormonal resistance in prostate cancer patients. J Clin Lab Analysis 1998;12:20-5.
37. Tsao KC, Wu JT. Development of an ELISA for the detection of serum chromogranin A (CgA) in prostate and non-neuroendocrine carcinomas. Clin Chim Acta 2001;313:21-9.
38. Bollito E, Berruti A, Bellina M, et al. Relationship between neuroendocrine features and prognostic parameters in human prostate adenocarcinoma. Ann Oncol 2001;12:S159-64.
39. Wu JT, Wu TL, Chang CP, Tsao KC, Sun CF. Different patterns of serum chromogranin A in patients with prostate cancer with and without undergoing hormonal therapy. J Clin Lab Analysis 1999;13:308-11.
40. Deftos LJ, Nakada S, Burton DW, et al. Immunoassay and immunohistology studies of chromogranin A as a neuroendocrine marker in patients with carcinoma of the prostate. Urology 1996;48:58-62.
41. Berruti A, Dogliotti L, Mosca A, et al. Circulating neuroendocrine markers in patients with prostate carcinoma. Cancer (Phila) 2000;88: 2590-7.
42. Wu JT, Erickson AJ, Tsao KC, Wu TL, Sun CF. Elevated serum chromogranin A is detectable in patients with carcinomas at advanced disease stages. Ann Clin Lab Sci 2000;30:175-8.
43. Deftos LJ, Abrahamsson PA. Granins and prostate cancer. Urology 1998;51:141-5.
44. Kimura N, Hoshi S, Takahashi M, et al. Plasma chromogranin A in prostatic carcinoma and neuroendocrine tumors. J Urol 1997;157: 565-8.
45. Ferrero-Pous M, Hersant AM, Pecking A, Bresard-Leroy M, Pichon MF. Serum chromogranin-A in advanced prostate cancer. BJU Int 2001;88:790-6.
46. Cheville JC, Tindall D, Boelter C, et al. Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival. Cancer (Phila) 2002;95:1028-36.
47. Ahlegren G, Pedersen K, Lundberg S, et al. Neuroendocrine differentiation is not prognostic of failure after radical prostatectomy but correlates with tumor volume. Urology 2000;56:1011-5.
48. Lilleby W, Paus E, Skovlund E, Fossa SD. Prognostic value of neuroendocrine serum markers and PSA in irradiated patients with pN0 localized prostate cancer. Prostate 2001;46:126-33.
49. Zaky Ahel M, Kovacic K, Kraljic I, Tarle M. Oral estramustine therapy in serum chromogranin A-positive stage D3 prostate cancer patients. Anticancer Res 2001;21:1475-9.
50. Isshiki S, Akakura K, Komiya A, et al. Chromogranin a concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer. J Urol 2002;167:512-5.
51. Hayes JD, Pulford DJ. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 1995;30:445-600.
52. Jeronimo C, Usadel H, Henrique R, et al. Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J Natl Cancer Institute (Bethesda) 2001;93: 1747-52.
53. Chu DC, Chuang CK, Fu JB, et al. The use of real-time quantitative polymerase chain reaction to detect hypermethylation of the CpG islands in the promoter region flanking the GSTP1 gene to diagnose prostate carcinoma. J Urol 2002;167:1854-8.
54. Brooks JD, Weinstein M, Lin X, et al. CG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasia. Cancer Epidemiol Biomark Prev 1998;7:531-6.
55. Cairns P, Esteller M, Herman JG, et al. Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. Clin Cancer Res 2001;7:2727-30.
56. Lin X, Tascilar M, Lee WH, et al. GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells. Am J Pathol 2001;159:1815-26.
57. Lee WH, Morton RA, Epstein JI, et al. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci USA 1994;91:11733-7.
58. Lee WH, Isaacs WB, Bova GS, Nelson WG. CG island methylation changes near the GSTP1 gene in prostatic carcinoma cells detected using the polymerase chain reaction: a new prostate cancer biomarker. Cancer Epidemiol Biomark Prev 1997;6:443-50.
59. Goessl C, Muller M, Heicappell R, et al. DNA-based detection of prostate cancer in urine after prostatic massage. Urology 2001;58: 335-8.
60. Millar DS, Ow KK, Paul CL, et al. Detailed methylation analysis of the glutathione S-transferase pi (GSTP1) gene in prostate cancer. Oncogene 1999;18:1313-24.
61. Cookson MS, Reuter VE, Linkov I, Fair WR. Glutathione-S-transferase P1 (GST-pi) class expression by immunohistochemistry in benign and malignant prostate tissue. J Urol 1997;157:673-6.
62. Moskaluk CA, Durray PH, Cowan KH, Linehan M, Merino MJ. Immunohistochemical expression of pi-class glutathione-S-transferase is down regulated in adenocarcinoma of the prostate. Cancer (Phila) 1997; 79:1595-9.
63. Jeronimo C, Varzim G, Henrique R, et al. I105V polymorphism and promoter methylation of the GSTP1 gene in prostate adenocarcinoma. Cancer Epidemiol Biomark Prev 2002;11:445-50.
64. Kote-Jarai Z, Easton D, Edwards SM, et al. Relationship between glutathione S-transferase M1, P1 and T1 polymorphisms and early onset prostate cancer. Pharmacogenetics 2001;11:325-30.
65. Gsur A, Haidinger G, Hinteregger S, et al. Polymorphisms of glutathione-S-transferase genes (GSTP1, GSTM1 and GSTT1) and prostate-cancer risk. Int J Cancer 2001;95:152-5.
66. Wadelius M, Autrup JL, Stubbins MJ, et al. Polymorphisms in NAT2, CYP2D6, CYP2C19 and GSTP1 and their association with prostate cancer. Pharmacogenetics 1999;9:333-40.
67. Steinhoff C, Franke KH, Golka K, et al. Glutathione transferase isozyme genotypes in patients with prostate and bladder carcinoma. Archiv Toxicol 2000;74:521-6.
68. Ho GY, Knapp M, Freije D, et al. Transmission/disequilibrium tests of androgen receptor and glutathione S-transferase pi variants in prostate cancer families. Int J Cancer 2002;98:938-42.
69. Maruyama R, Toyooka S, Toyooka KO, et al. Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clinical Cancer Res 2002;8:514-9.
70. Lin X, Asgari K, Putzi MJ, et al. Reversal of GSTP1 CpG island hypermethylation and reactivation of pi-class glutathione S-transferase (GSTP1) expression in human prostate cancer cells by treatment with procainamide. Cancer Res 2001;61:8611-6.
71. Reiter RE, Gu Z, Watabe T, et al. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci USA 1998;95:1735-40.
72. Reiter RE, Magi-Galluzzi C, Hemmati H, et al. Two genes upregulated in androgen independent prostate cancer are also selectively expressed in the basal cells of normal prostate epithelium. J Urol 1997; 157:269A.
73. Gu Z, Thomas G, Yamashiro J, et al. Prostate stem cell antigen (PSCA) expression increases with high Gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene 2000;19:1288-96.
74. Hara N, Kasahara T, Kawasaki T, et al. Reverse transcription-polymerase chain reaction detection of prostate-specific antigen, prostate-specific membrane antigen, and prostate stem cell antigen in one milliliter of peripheral blood: value for the staging of prostate cancer. Clin Cancer Res 2002;8:1794-9.
75. Jalkut MW, Reiter RE. Role of prostate stem cell antigen in prostate cancer research. Curr Opin Urol 2002;12:401-6.
76. Christiansen JJ, Rajasekaran SA, Moy P, et al. Polarity of prostate specific membrane antigen, prostate stem cell antigen, and prostate specific antigen in prostate tissue and in a cultured epithelial cell line. Prostate 2003;55:9-19.
77. Ross S, Spencer SD, Holcomb I, et al. Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate. Cancer Res 2002;62:2546-53.
78. Saffran DC, Raitano AB, Hubert RS, et al. Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts. Proc Natl Acad Sci USA 2001;98:2658-63.
79. Dannull J, Diener PA, Prikler L, et al. Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer. Cancer Res 2000;60:5522-8.
80. Reiter RE, Sato I, Thomas G, et al. Coamplification of prostate stem cell antigen (PSCA) and MYC in locally advanced prostate cancer. Genes Chromosomes Cancer 2000;27:95-103.
81. Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 1987;7:927-35.
82. Israeli RS, Powell CT, Corr JG, Fair WR, Heston WD. Expression of the prostate-specific membrane antigen. Cancer Res 1994;54: 1807-11.
83. Pinto JT, Suffoletto BP, Berzin TM, et al. Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res 1996;2:1445-51.
84. Chung LWK, Isaacs WB, Simons JW (eds). Prostate cancer: biology, genetics, and the new therapeutics. Totowa, NJ: Humana Press Inc.; 2001.
85. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997;3:81-5.
86. Murphy GP, Kenny GM, Ragde H, et al. Measurement of serum prostate-specific membrane antigen, a new prognostic marker for prostate cancer. Urology 1998;51:89-97.
87. Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma. Cancer (Phila) 1998;83:2256-61.
88. Sweat SD, Pacelli A, Murphy GP, Bostwick DG. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology 1998;52:637-40.
89. Murphy GP, Tino WT, Holmes EH, et al. Measurement of prostate-specific membrane antigen in the serum with a new antibody. Prostate 1996;28:266-71.
90. Murphy GP, Maguire RT, Rogers B, et al. Comparison of serum PSMA, PSA levels with results of Cytogen-356 ProstaScint scanning in prostatic cancer patients. Prostate 1997;33:281-5.
91. Troyer JK, Beckett ML, Wright GL Jr. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer 1995;62:552-8.
92. Murphy G, Ragde H, Kenny G, et al. Comparison of prostate specific membrane antigen, and prostate specific antigen levels in prostatic cancer patients. Anticancer Res 1995;15:1473-9.
93. Beckett ML, Cazares LH, Vlahou A, Schellhammer PF, Wright GL Jr. Prostate-specific membrane antigen levels in sera from healthy men and patients with benign prostate hyperplasia or prostate cancer. Clin Cancer Res 1999;5:4034-40.
94. Douglas TH, Morgan TO, McLeod DG, et al. Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients. Cancer 1997;80:107-14.
95. Wright GL Jr, Grob BM, Haley C, et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy, Urology 1996;48:326-34.
96. Xiao Z, Adam BL, Cazares LH, et al. Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. Cancer Res 2001;61:6029-33.
97. Tjoa B, Boynton A, Kenny G, et al. Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity. Prostate 1996;28:65-9.
98. O'Keefe DS, Uchida A, Bacich DJ, et al. Prostate-specific suicide gene therapy using the prostate-specific membrane antigen promoter and enhancer. Prostate 2000;45:149-57.
99. Uria JA, Velasco G, Santamaria I, Ferrando A, Lopez-Otin C. Prostate-specific membrane antigen in breast carcinoma. Lancet 1997; 349:1601.
100. Shay JW, Werbin H, Wright WE. Telomere shortening may contribute to aging and cancer: a perspective. Mol Cell Differ 1994;2:1-22.
101. Iczkowski KA, Pantazis CG, McGregor DH, Wu Y, Tawfik OW. Telomerase reverse transcriptase subunit immunoreactivity: a marker for high-grade prostate carcinoma. Cancer (Phila) 2002;95:2487-93.
102. Sommerfeld HJ, Meeker AK, Piatyszek MA, et al. Telomerase activity: a prevalent marker of malignant human prostate tissue. Cancer Res 1996;56:218-22.
103. Orlando C, Gelmini S, Selli C, Pazzagli M. Telomerase in urological malignancy. J Urol 2001;166:666-73.
104. Lin Y, Uemura H, Fujinami K, et al. Telomerase activity in primary prostate cancer. J Urol 1997;157:1161-5.
105. Wang Z, Ramin SA, Tsai C, et al. Telomerase activity in prostate sextant needle cores from radical prostatectomy specimens. Urol Oncol 2001;6:57-62.
106. Latil A, Vidaud D, Valeri A, et al. htert expression correlates with MYC over-expression in human prostate cancer. Int J Cancer 2000;89: 172-6.
107. Liu BC, LaRose I, Weinstein LJ, et al. Expression of telomerase subunits in normal and neoplastic prostate epithelial cells isolated by laser capture microdissection. Cancer (Phila) 2001;92:1943-8.
108. Wullich B, Rohde V, Oehlenschlager B, et al. Focal intratumoral heterogeneity for telomerase activity in human prostate cancer. J Urol 1999;161:1997-2001.
109. Koeneman KS, Pan CX, Jin JK, et al. Telomerase activity, telomere length, and DNA ploidy in prostatic intraepithelial neoplasia (PIN). J Urol 1998;160:1533-9.
110. Chieco P, Bertaccini A, Giovannini C, Stecca BA, Martorana G. Telomerase activity in touch-imprint cell preparations from fresh prostate needle biopsy specimens. Eur Urol 2001;40:666-72.
111. Zhang W, Kapusta LR, Slingerland JM, Klotz LH. Telomerase activity in prostate cancer, prostatic intraepithelial neoplasia, and benign prostatic epithelium. Cancer Res 1998;58:619-21.
112. Paradis V, Dargere D, Laurendeau I, et al. Expression of the RNA component of human telomerase (hTR) in prostate cancer, prostatic intraepithelial neoplasia, and normal prostate tissue. J Pathol 1999;189: 213-8.
113. Straub B, Muller M, Krause H, et al. Molecular staging of surgical margins after radical prostatectomy by detection of telomerase activity. Prostate 2001;49:140-4.
114. Ohyashiki K, Yahata N, Ohyashiki JH, et al. A combination of semiquantitative telomerase assay and in-cell telomerase activity measurement using exfoliated urothelial cells for the detection of urothelial neoplasia. Cancer (Phila) 1998;83:2554-60.
115. Wang Z, Ramin SA, Tsai C, et al. Detection of telomerase activity in prostatic fluid specimens. Urol Oncol 2000;6:4-9.
116. Kallakury BV, Brien TP, Lowry CV, et al. Telomerase activity in human benign prostate tissue and prostatic adenocarcinomas Diagn Mol Pathol 1997;6:192-8.
117. Scates DK, Muir GH, Venitt S, Carmichael PL. Detection of telomerase activity in human prostate: a diagnostic marker for prostatic cancer? Br J Urol 1997;80:263-8.
118. Takahashi C, Miyagawa I, Kumano S, Oshimura M. Detection of telomerase activity in prostate cancer by needle biopsy. Eur Urol 1997; 32:494-8.
119. Lin Y, Uemura H, Fujinami K, et al. Detection of telomerase activity in prostate needle-biopsy samples. Prostate 1998;36:121-8.
120. Caldarera E, Crooks NH, Muir GH, Pavone-Macaluso M, Carmichael PL. An appraisal of telomerase activity in benign prostatic hyperplasia. Prostate 2000;45:267-70.
121. Donaldson L, Fordyce C, Gilliland F, et al. Association between outcome and telomere DNA content in prostate cancer. J Urol 1999; 162:1788-92.
122. Meid FH, Gygi CM, Leisinger HJ, Bosman FT, Benhattar J. The use of telomerase activity for the detection of prostatic cancer cells after prostatic massage. J Urol 2001;165:1802-5.
123. Magee JA, Araki T, Patil S, et al. Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res 2001;61: 5692-6.
124. Dhanasekaran SM, Barrette TR, Ghosh D, et al. Delineation of prognostic biomarkers in prostate cancer. Nature (Lond) 2001;412: 822-6.
125. Srikantan V, Valladares M, Rhim JS, Moul JW, Srivastava S. HEPSIN inhibits cell growth/invasion in prostate cancer cells. Cancer Res 2002;62:6812-6.
126. Carpten J, Nupponen N, Isaacs S, et al. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet 2002;30:181-4.
127. Casey G, Neville PI, Plummer SI, et al. RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat Genet 2002;32:581-3.
128. Qing J, Wei D, Maher VM, McCormick JJ. Cloning and characterization of a novel gene encoding a putative transmembrane protein with altered expression in some human transformed and tumor-derived cell lines. Oncogene 1999;18:335-42.
129. Zenklusen JC, Conti CJ, Green ED. Mutational and functional analyses reveal that ST7 is a highly conserved tumor-suppressor gene on human chromosome 7q31. Nat Genet 2001;27:392-8.
130. Dong SM, Sidransky D. Absence of ST7 gene alterations in human cancer. Clin Cancer Res 2002;8:2939-41.
131. Varambally S, Dhanasekaran SM, Zhou M, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature (Lond) 2002;419:624-9.
132. Rhodes DR, Sanda MG, Otte AP, Chinnaiyan AM, Rubin MA. Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. J Natl Cancer Inst (Bethesda) 2003;95:661-8.
133. Petricoin EF, Ornstein DK, Paweletz CP, et al. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst (Bethesda) 2002;94:1576-8.
134. Hammond MEH, Taube SE. Issues and barriers to development of clinically useful tumor markers: a development pathway proposal. Semin Oncol 2002;29:213-21.
135. Simon R, Altman DG. Statistical aspects of prognostic factor studies in oncology. Br J Cancer 1994;69:979-85.